A deal's done: Less than a month after receiving Novartis' stall of vaccines products, GlaxoSmithKline has ended the yearlong pricing standoff with United Kingdom's National Health Service over meningitis B vaccine Bexsero.
Novartis, a leader among companies using the immune system to fight cancer, is betting up to $750 million on a promising therapeutic approach from Aduro Biotech, widening its arsenal of potential treatments.
It's official: Amgen is appealing last week's ruling in a fight over biosimilar Neupogen. The California-based biotech, aiming to protect its $1.2 billion branded drug, wants to bar Novartis from launching its biosimilar version, Zarxio.
Semma Therapeutics aims to provide beta cells--the pancreatic cells that produce insulin--to patients with Type 1 diabetes. If the startup can get beyond early research, an implantable device that creates insulin via these stem cell-derived beta cells could replace daily insulin injections and transform patient care.
Novartis became the first to win approval among a scrum of drugmakers with new antibody treatments for autoimmune disease, but its rivals are bounding toward the FDA with positive data of their own.
As Big Pharma casts an eye toward med tech to diversify its offerings and capitalize on a growing market, Novartis is jumping on the bandwagon with new digital and patient monitoring devices.
Newcomers showed off at this year's American Academy of Dermatology meeting, with more than one touting Stelara-beating data--and prepping the market for an all-out psoriasis war.
What's better than a new drug launch? A launch destined for greatness, of course. For sales and marketing teams, that's about as much job security as you can get.
Novartis CEO Joseph Jimenez presides over one of the industry's largest R&D budgets, committing about $10 billion a year to drug development. But the American-born executive, in contrast to his predecessor, has made a habit of ditching projects when they start to look futile, a philosophy that trickles down to Novartis' lab work.
Austin, Texas, biotech Aeglea Biotherapeutics raised $44 million in Series B cash to bankroll its enzyme-replacement therapy for a rare metabolic disorder, with Eli Lilly and Novartis leading the round.